

Bertram Pitt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/421370/bertram-pitt-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

226
papers

23,016
citations

50
h-index

150
g-index

261
ext. papers

28,980
ext. citations

9.2
avg, IF

6.72
L-index

#	Paper	IF	Citations
226	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.. <i>Diabetes Care</i> , 2022 ,	14.6	3
225	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.. <i>Kidney International Reports</i> , 2022 , 7, 36-45	4.1	11
224	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 125-134	6.7	5
223	Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk.. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 822-824	4.5	0
222	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	2
221	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. <i>Cleveland Clinic Journal of Medicine</i> , 2021 , 88, 601-606	2.8	
220	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	3
219	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	2
218	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2021 , 24, 230	12.3	4
217	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
216	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	1
215	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. <i>Circulation</i> , 2021 ,	16.7	10
214	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.. <i>European Heart Journal</i> , 2021 ,	9.5	33
213	Spirolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1211-1221	15.1	1
212	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1554-1563	6.1	4
211	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1426-1430	6.7	5
210	Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 325-335	7.9	6

209	Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. <i>European Journal of Pharmacology</i> , 2021 , 898, 173988	5.3	12
208	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1308-1320	6.1	1
207	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021 , 42, 2373-2385	3.5	4
206	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e008075	7.6	2
205	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. <i>International Journal of Cardiology</i> , 2021 , 332, 35-37	3.2	2
204	New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review. <i>Sleep Medicine Reviews</i> , 2021 , 57, 101473	10.2	4
203	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 142-152	15.1	17
202	Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. <i>Hypertension</i> , 2021 , 78, 74-81	8.5	10
201	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 117-128	59.2	408
200	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 129-139	59.2	243
199	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021 , 143, 540-552	16.7	76
198	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. <i>European Heart Journal</i> , 2021 ,	9.5	3
197	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>ESC Heart Failure</i> , 2021 , 8, 1130-1138	3.7	8
196	Estimated plasma volume status in heart failure: clinical implications and future directions. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1159-1172	6.1	10
195	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 2252-2263	59.2	103
194	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1065-1072	8	6
193	A preliminary study on the relationship between sleep, depression and cardiovascular dysfunction in a 4 sample population. <i>IJC Heart and Vasculature</i> , 2021 , 35, 100814	2.4	
192	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2

191	An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 1017-1023	5.9	0
190	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020 , 22, 1615-1624	12.3	9
189	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
188	Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. <i>Hypertension</i> , 2020 , 76, 144-149	8.5	13
187	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2836-2850	15.1	36
186	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEBUS trial. <i>European Heart Journal</i> , 2020 , 41, 1673-1683	9.5	17
185	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 834-844	12.3	13
184	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1390-1398 ¹⁵	12.3	15
183	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020 , 22, 848-855	12.3	9
182	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e006638	7.6	3
181	Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1392-1401	6.1	11
180	Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 901-903	12.3	5
179	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020 , 125, 1655-1660	3	2
178	Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 77, 323-331	3.1	11
177	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 188-198	7.9	20
176	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1402-1411	12.3	10
175	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020 , 38, 420-425	1.9	5
174	Medical Therapies for Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2020 , 75, 23-32	8.5	25

173	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	20
172	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020 , 8, 1009-1020	7.9	6
171	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 383, 2219-2229	59.2	347
170	Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. <i>Hypertension</i> , 2020 , 76, 1045-1054	8.5	11
169	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) Trials. <i>Clinical Research in Cardiology</i> , 2020 , 109, 194-204	6.1	15
168	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 898-901	12.3	25
167	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. <i>Circulation</i> , 2019 , 140, 1463-1476	16.7	163
166	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
165	Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. <i>European Heart Journal Supplements</i> , 2019 , 21, A55-A60	1.5	8
164	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019 , 12, e005766	7.6	14
163	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1215-1225	6.1	10
162	The renin-angiotensin-aldosterone system and its suppression. <i>Journal of Veterinary Internal Medicine</i> , 2019 , 33, 363-382	3.1	108
161	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 664-675	7.9	28
160	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
159	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
158	Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial. <i>Clinical Cardiology</i> , 2019 , 42, 1106-1112	3.3	9
157	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019 , 50, 345-356	4.6	80
156	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019 , 50, 333-344	4.6	70

155	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 345-351	12.3	28
154	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019 , 218, 66-74	4.9	12
153	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. <i>JACC: Heart Failure</i> , 2019 , 7, 1012-1021	7.9	14
152	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006539	7.6	36
151	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 65-76	7.9	32
150	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019 , 7, 25-32	7.9	32
149	Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstlve hearT failure: The COFFEE-IT study. <i>Pharmacological Research</i> , 2019 , 141, 46-52	10.2	2
148	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019 , 123, 611-617	3	14
147	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019 , 108, 477-486	6.1	39
146	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 231-241	4.3	16
145	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019 , 40, 880-886	9.5	23
144	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 653-661	7.9	34
143	The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 525-535	4.1	10
142	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1326-1334	12.3	86
141	An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1035-1043	2.9	2
140	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). <i>American Journal of Cardiology</i> , 2018 , 121, 1015-1020	3	10
139	Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution. <i>JACC Basic To Translational Science</i> , 2018 , 3, 25-34	8.7	12
138	Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018 , 5, 257-266	3.7	34

137	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
136	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 727-735	15.1	18
135	Spirolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018 , 31, 407-414	2.3	20
134	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018 , 20, 323-331	12.3	11
133	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging: Potential Approach to Research and Clinical Practice. <i>Circulation Research</i> , 2018 , 122, 23-25	15.7	9
132	Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. <i>Heart</i> , 2018 , 104, 1843-1849	5.1	13
131	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004457	7.6	20
130	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spirolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 313-320	3.3	33
129	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 815-816	12.3	5
128	Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials. <i>American Heart Journal</i> , 2018 , 195, 60-69	4.9	14
127	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. <i>Clinical Research in Cardiology</i> , 2018 , 107, 49-59	6.1	14
126	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , 2018 , 11, e004926	7.6	13
125	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 689-697	7.9	36
124	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1000-1005	16.2	24
123	Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018 , 20, 1247-1251	12.3	12
122	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. <i>American Journal of Medicine</i> , 2018 , 131, 555-564.e3	2.4	29
121	Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005312	7.6	19
120	Future large-scale clinical trials in cardiovascular medicine: challenges and uncertainties. <i>European Journal of Heart Failure</i> , 2018 , 20, 1645-1648	12.3	5

119	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005288	7.6	23
118	Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. <i>Clinical Research in Cardiology</i> , 2018 , 107, 1192-1195	6.1	4
117	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2018 , 39, 4257-4265	9.5	23
116	Revisiting hyperkalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , 2018 , 20, 1255	12.3	1
115	Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: "Mind the Gap". <i>American Journal of Hypertension</i> , 2018 , 31, 1087-1089	2.3	1
114	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , 2018 , 36, 1463-1473	4.4	11
113	Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. <i>ESC Heart Failure</i> , 2018 , 5, 592-602	3.7	30
112	Mineralocorticoid Receptor Antagonists in ST-Segment Elevation Myocardial Infarction. <i>JAMA Internal Medicine</i> , 2018 , 178, 920-921	11.5	1
111	Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHEBUS and OPTIMAAL trials. <i>Journal of Hypertension</i> , 2018 , 36, 1736-1742	1.9	7
110	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	13
109	A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 399-407	6.9	50
108	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	28
107	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. <i>European Journal of Heart Failure</i> , 2017 , 19, 974-986	12.3	23
106	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. <i>JACC: Heart Failure</i> , 2017 , 5, 399-407	7.9	22
105	Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017 , 376, 1690-1692	59.2	135
104	Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>Clinical Research in Cardiology</i> , 2017 , 106, 722-733	6.1	7
103	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). <i>Circulation</i> , 2017 , 136, 982-992	16.7	55
102	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1043-1052	12.3	22

101	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 241-252	7.9	90
100	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , 2017 , 188, 99-108	4.9	40
99	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1186-1197	12.3	55
98	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017 , 14, 238-250	14.8	322
97	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. <i>JACC: Heart Failure</i> , 2017 , 5, 782-791	7.9	18
96	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 783-800		33
95	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 844-858	7.4	37
94	Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	13
93	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, S10-S19	1.9	15
92	Steroid and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2017 , 243, 271-305	3.2	60
91	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 792-799	12.3	28
90	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2017 , 19, 271-279	12.3	22
89	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 48-57	6.4	48
88	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016 , 37, 2105-14	9.5	184
87	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1769-1776	6.9	31
86	Roadmap for cardiovascular prevention trials in chronic kidney disease. <i>Lancet, The</i> , 2016 , 388, 1964-1966	6	8
85	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	36
84	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. <i>JACC: Heart Failure</i> , 2016 , 4, 419-27	7.9	34

83	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , 2016 , 18, 1175-81	12.3	11
82	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart MicroAgeing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>European Journal of Heart Failure</i> , 2016 , 18, 1175-81	11.4	35
81	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , 2016 , 216, 46-51	3.2	19
80	Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1435-48	4	21
79	The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 659-65	4.1	8
78	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
77	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1575-89	15.1	60
76	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. <i>Pharmacological Research</i> , 2016 , 113, 585-591	10.2	72
75	Prognostic Value of the Thrombolysis in Myocardial Infarction Risk Score in ST-Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction (from the EPHEBUS Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 1442-1447	3	7
74	Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. <i>European Journal of Heart Failure</i> , 2016 , 18, 216	12.3	1
73	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , 2015 , 8, 826-31	7.6	28
72	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015 , 116, 1304-10	3	3
71	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015 , 132, 402-14	16.7	263
70	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015 , 36, 2310-7	9.5	20
69	Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015 , 17, 224-32	12.3	62
68	Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015 , 169, 305-14	4.9	18
67	Cardiovascular drug development: is it dead or just hibernating?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1567-82	15.1	104
66	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1668-1682	15.1	89

65	Prognostic Value of Estimated Plasma Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2015 , 3, 886-93	7.9	66
64	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1973-5	27.4	41
63	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015 , 88, 1427-1433	9.9	66
62	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015 , 8, 1052-8	7.6	54
61	New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. <i>Hypertension</i> , 2015 , 66, 731-8	8.5	46
60	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>European Journal of Heart Failure</i> , 2015 , 17, 1057-65	12.3	106
59	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015 , 17, 1144-51	12.3	63
58	My approach to patients with heart failure and a normal ejection fraction. <i>Trends in Cardiovascular Medicine</i> , 2015 , 25, 164-5	6.9	
57	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <i>Circulation</i> , 2015 , 131, 34-42	16.7	534
56	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015 , 169, 323-33	4.9	62
55	Spironolactone for heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , 2014 , 370, 1383-92	59.2	1365
54	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
53	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 471-82	12.3	90
52	Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). <i>American Journal of Cardiology</i> , 2014 , 114, 737-42	3	44
51	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014 , 35, 2295-302	9.5	100
50	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. <i>Heart</i> , 2014 , 100, 1681-7	5.1	21
49	Predictors of contemporary coronary artery bypass grafting outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 2720-6.e1-2	1.5	16
48	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2281-93	15.1	313

47	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
46	Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circulation: Heart Failure</i> , 2014 , 7, 573-9	7.6	112
45	Heart failure: the role for mineralocorticoid receptor antagonists. <i>Swiss Medical Weekly</i> , 2014 , 144, w13959	3.5	3
44	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013 , 167, 1677-87	3.2	82
43	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013 , 34, 2453-63	9.5	282
42	The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure. <i>Heart Failure Clinics</i> , 2012 , 8, 247-53	3.3	4
41	The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. <i>Heart Failure Reviews</i> , 2012 , 17, 573-9	5	12
40	Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). <i>American Journal of Cardiology</i> , 2012 , 109, 1239-46	3	42
39	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012 , 14, 668-75	12.3	60
38	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , 2011 , 364, 11-21	59.2	1890
37	Clinical efficacy of aldosterone-blocking agents. <i>European Heart Journal Supplements</i> , 2011 , 13, B36-B39	1.5	2
36	Male gender, diabetes, COPD, anemia, and creatinine clearance <i>Annals of Internal Medicine</i> , 2010 , 152, JC4-2, JC4-3	8	5
35	Review: remote patient monitoring of patients with heart failure reduces mortality and heart failure admissions. <i>Annals of Internal Medicine</i> , 2010 , 152, JC4-3, JC4-2	8	2
34	RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. <i>Heart</i> , 2009 , 95, 1205-8	5.1	5
33	Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?. <i>Current Heart Failure Reports</i> , 2009 , 6, 112-6	2.8	2
32	Lipid levels after acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1440-51	15.1	111
31	Aldosterone blockade in patients with chronic heart failure. <i>Cardiology Clinics</i> , 2008 , 26, 15-21, v	2.5	7
30	N-terminal pro-B-type natriuretic peptide concentrations > or = 100 ng/l increased risk of all-cause mortality. <i>Evidence-Based Medicine</i> , 2008 , 13, 26		

29	History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. <i>Hypertension</i> , 2008 , 52, 271-8	8.5	21
28	Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2008 , 10, 288-94	6	1
27	Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. <i>Circulation</i> , 2007 , 115, 2976-82; discussion 2982	16.7	25
26	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>Evidence-Based Medicine</i> , 2007 , 12, 107		
25	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>ACP Journal Club</i> , 2007 , 147, 12		
24	A primer on aldosterone for gynecologists/obstetricians. <i>Journal of reproductive medicine, The</i> , 2007 , 52, 153-8		
23	Percutaneous coronary intervention plus optimal medical therapy was not more effective than medical therapy alone in stable CAD. <i>ACP Journal Club</i> , 2007 , 147, 12		
22	Aldosterone receptor antagonists for heart failure: current status, future indications. <i>Cleveland Clinic Journal of Medicine</i> , 2006 , 73, 257-60, 264-8	2.8	7
21	Role of aldosterone blockade in heart failure. <i>Heart Failure Clinics</i> , 2005 , 1, 49-56	3.3	1
20	Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 425-31	15.1	284
19	Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 70-1		
18	Generic drugs in cardiology: will they reduce health care costs?. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 10-3	15.1	10
17	Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHEsus studies. <i>Molecular and Cellular Endocrinology</i> , 2004 , 217, 53-8	4.4	84
16	Task Force 2: Investigator Participation in Clinical Research. <i>Circulation</i> , 2004 , 110, 2517-2524	16.7	1
15	Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>New England Journal of Medicine</i> , 2003 , 348, 1309-21	59.2	3668
14	OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003 , 16, A11	2.3	3
13	Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 164-8	3	43
12	Aldosterone blockade in patients with systolic left ventricular dysfunction. <i>Circulation</i> , 2003 , 108, 1790-4	16.7	43

11	Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?. <i>Journal of Cardiac Failure</i> , 2002 , 8, S491-3	3.3	6
10	Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. <i>American Journal of Hypertension</i> , 2002 , 15, 22S-27S	2.3	15
9	The EPHEBUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. <i>Cardiovascular Drugs and Therapy</i> , 2001 , 15, 79-87	3.9	248
8	Risk stratification for the detection of preclinical coronary artery disease. <i>Circulation</i> , 1999 , 99, 2610-2	16.7	27
7	Effects of Angiotensin II Antagonists in Comparison to ACE Inhibitors in Patients with Heart Failure due to Systolic Left Ventricular Dysfunction. <i>Heart Failure Reviews</i> , 1999 , 3, 221-232	5	5
6	The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>New England Journal of Medicine</i> , 1999 , 341, 709-17 ²	59.2	6637
5	Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 1946-52	5.6	116
4	Quinapril prevents hypertension and enhanced vascular reactivity in nitroarginine-treated rats. <i>Blood Pressure</i> , 1997 , 6, 117-24	1.7	3
3	Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. <i>Circulation</i> , 1995 , 92, 2419-25	16.7	186
2	An automated system for ST segment and arrhythmia analysis in exercise radionuclide ventriculography. <i>IEEE Transactions on Biomedical Engineering</i> , 1986 , 33, 585-93	5	15
1	Depression, Anxiety, Anger, and Heart Failure ³⁴⁻⁴⁸		1